Do analysts recommend INTS or VCNX?

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 846.97%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Intensity Therapeutics is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intensity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is INTS or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Intensity Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Intensity Therapeutics N/A -116.61% -94.01% Vaccinex N/A N/A -383.58%

Does the media prefer INTS or VCNX?

In the previous week, Intensity Therapeutics had 6 more articles in the media than Vaccinex. MarketBeat recorded 7 mentions for Intensity Therapeutics and 1 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 beat Intensity Therapeutics' score of -0.02 indicating that Vaccinex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intensity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CALC or VCNX?

CalciMedica presently has a consensus target price of $10.00, indicating a potential upside of 1,381.26%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CALC or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -155.24% Vaccinex N/A N/A -383.58%

Does the media refer more to CALC or VCNX?

In the previous week, CalciMedica had 10 more articles in the media than Vaccinex. MarketBeat recorded 11 mentions for CalciMedica and 1 mentions for Vaccinex. CalciMedica's average media sentiment score of 0.19 beat Vaccinex's score of 0.00 indicating that CalciMedica is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CalciMedica 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend KPRX or VCNX?

Kiora Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 292.16%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Kiora Pharmaceuticals is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is KPRX or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Kiora Pharmaceuticals N/A -63.38% -44.33% Vaccinex N/A N/A -383.58%

Does the media refer more to KPRX or VCNX?

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for Kiora Pharmaceuticals and 1 mentions for Vaccinex. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat Vaccinex's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kiora Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, VCNX or PHXM?

PHAXIAM Therapeutics has lower revenue, but higher earnings than Vaccinex. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vaccinex $388K 5.58 -$20.25M -$48.27 N/A PHAXIAM Therapeutics N/A N/A -$240K N/A N/A

Is VCNX or PHXM more profitable?

Company Net Margins Return on Equity Return on Assets Vaccinex N/A N/A -383.58% PHAXIAM Therapeutics N/A N/A N/A

Do analysts rate ADIL or VCNX?

Adial Pharmaceuticals presently has a consensus target price of $15.63, indicating a potential upside of 292.59%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than Vaccinex. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adial Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Vaccinex 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ADIL or VCNX more profitable?

Vaccinex's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Adial Pharmaceuticals N/A -162.82% -127.58% Vaccinex N/A N/A -383.58%

Does the media refer more to ADIL or VCNX?

In the previous week, Adial Pharmaceuticals had 3 more articles in the media than Vaccinex. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 1 mentions for Vaccinex. Adial Pharmaceuticals' average media sentiment score of 0.62 beat Vaccinex's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adial Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vaccinex 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vaccinex (VCNX) Competitors

$0.83 0.00 (0.00%)

As of 08/13/2026 03:33 PM Eastern

Compare

VCNX vs. INTS, CALC, KPRX, PHXM, and ADIL

Should you buy Vaccinex stock or one of its competitors? Vaccinex's main competitors and comparable companies include Intensity Therapeutics (INTS), CalciMedica (CALC), Kiora Pharmaceuticals (KPRX), PHAXIAM Therapeutics (PHXM), and Adial Pharmaceuticals (ADIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Vaccinex compare to Intensity Therapeutics?

Intensity Therapeutics (NASDAQ:INTS) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

Intensity Therapeutics has a beta of 2.76, suggesting that its stock price is 176% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market.

In the previous week, Intensity Therapeutics had 6 more articles in the media than Vaccinex. MarketBeat recorded 7 mentions for Intensity Therapeutics and 1 mentions for Vaccinex. Vaccinex's average media sentiment score of 0.00 beat Intensity Therapeutics' score of -0.02 indicating that Vaccinex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intensity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.7% of Intensity Therapeutics shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 7.6% of Intensity Therapeutics shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vaccinex's return on equity of 0.00% beat Intensity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intensity Therapeutics	N/A	-116.61%	-94.01%
Vaccinex	N/A	N/A	-383.58%

Intensity Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 846.97%. Given Intensity Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Intensity Therapeutics is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intensity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Intensity Therapeutics has higher earnings, but lower revenue than Vaccinex. Intensity Therapeutics is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intensity Therapeutics	N/A	N/A	-$11.61M	-$5.71	N/A
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A

Summary

Intensity Therapeutics beats Vaccinex on 9 of the 14 factors compared between the two stocks.

How does Vaccinex compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

CalciMedica has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

Vaccinex's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-155.24%
Vaccinex	N/A	N/A	-383.58%

Vaccinex has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A

In the previous week, CalciMedica had 10 more articles in the media than Vaccinex. MarketBeat recorded 11 mentions for CalciMedica and 1 mentions for Vaccinex. CalciMedica's average media sentiment score of 0.19 beat Vaccinex's score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CalciMedica	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

50.1% of Vaccinex shares are held by institutional investors. 28.3% of CalciMedica shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

CalciMedica presently has a consensus target price of $10.00, indicating a potential upside of 1,381.26%. Given CalciMedica's stronger consensus rating and higher probable upside, research analysts clearly believe CalciMedica is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

CalciMedica and Vaccinex tied by winning 7 of the 14 factors compared between the two stocks.

How does Vaccinex compare to Kiora Pharmaceuticals?

Kiora Pharmaceuticals (NASDAQ:KPRX) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Vaccinex's return on equity of 0.00% beat Kiora Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiora Pharmaceuticals	N/A	-63.38%	-44.33%
Vaccinex	N/A	N/A	-383.58%

Kiora Pharmaceuticals presently has a consensus price target of $10.00, indicating a potential upside of 292.16%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Kiora Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiora Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Vaccinex. MarketBeat recorded 3 mentions for Kiora Pharmaceuticals and 1 mentions for Vaccinex. Kiora Pharmaceuticals' average media sentiment score of 1.01 beat Vaccinex's score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kiora Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kiora Pharmaceuticals has higher revenue and earnings than Vaccinex. Kiora Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiora Pharmaceuticals	$16.02M	0.70	-$10.84M	-$2.51	N/A
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A

77.0% of Kiora Pharmaceuticals shares are held by institutional investors. Comparatively, 50.1% of Vaccinex shares are held by institutional investors. 0.5% of Kiora Pharmaceuticals shares are held by insiders. Comparatively, 51.5% of Vaccinex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiora Pharmaceuticals has a beta of -0.38, indicating that its stock price is 138% less volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market.

Summary

Kiora Pharmaceuticals beats Vaccinex on 10 of the 15 factors compared between the two stocks.

How does Vaccinex compare to PHAXIAM Therapeutics?

Vaccinex (NASDAQ:VCNX) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

50.1% of Vaccinex shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 51.5% of Vaccinex shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Vaccinex had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Vaccinex and 0 mentions for PHAXIAM Therapeutics. Vaccinex's average media sentiment score of 0.00 equaled PHAXIAM Therapeutics'average media sentiment score.

Company	Overall Sentiment
Vaccinex	Neutral
PHAXIAM Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Vaccinex	N/A	N/A	-383.58%
PHAXIAM Therapeutics	N/A	N/A	N/A

PHAXIAM Therapeutics has lower revenue, but higher earnings than Vaccinex.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A
PHAXIAM Therapeutics	N/A	N/A	-$240K	N/A	N/A

Vaccinex has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the broader market.

Summary

Vaccinex beats PHAXIAM Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Vaccinex compare to Adial Pharmaceuticals?

Adial Pharmaceuticals (NASDAQ:ADIL) and Vaccinex (NASDAQ:VCNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Adial Pharmaceuticals has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market. Comparatively, Vaccinex has a beta of 1.1, suggesting that its share price is 10% more volatile than the broader market.

Adial Pharmaceuticals has higher earnings, but lower revenue than Vaccinex. Adial Pharmaceuticals is trading at a lower price-to-earnings ratio than Vaccinex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$7.98M	-$7.98	N/A
Vaccinex	$388K	5.58	-$20.25M	-$48.27	N/A

In the previous week, Adial Pharmaceuticals had 3 more articles in the media than Vaccinex. MarketBeat recorded 4 mentions for Adial Pharmaceuticals and 1 mentions for Vaccinex. Adial Pharmaceuticals' average media sentiment score of 0.62 beat Vaccinex's score of 0.00 indicating that Adial Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adial Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vaccinex	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

16.4% of Adial Pharmaceuticals shares are owned by institutional investors. Comparatively, 50.1% of Vaccinex shares are owned by institutional investors. 1.9% of Adial Pharmaceuticals shares are owned by company insiders. Comparatively, 51.5% of Vaccinex shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vaccinex's return on equity of 0.00% beat Adial Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-162.82%	-127.58%
Vaccinex	N/A	N/A	-383.58%

Adial Pharmaceuticals presently has a consensus target price of $15.63, indicating a potential upside of 292.59%. Given Adial Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Adial Pharmaceuticals is more favorable than Vaccinex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Vaccinex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Adial Pharmaceuticals beats Vaccinex on 9 of the 14 factors compared between the two stocks.

Get Vaccinex News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCNX vs. The Competition

Export

Metric	Vaccinex	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.17M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.02	640.15	211.09	21.74
Price / Sales	5.58	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	-0.32	11.60	12.91	6.24
Net Income	-$20.25M	$2.77B	$3.45B	$347.60M
7 Day Performance	-15.89%	0.17%	1.12%	1.07%
1 Month Performance	-28.22%	0.35%	1.79%	1.03%
1 Year Performance	34.31%	161.52%	67.69%	20.77%

Vaccinex Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCNX Vaccinex	N/A	$0.83 flat	N/A	+34.1%	$2.17M	$388K	N/A	40
INTS Intensity Therapeutics	3.2964 of 5 stars	$4.28 +1.9%	$37.50 +776.4%	-44.8%	$11.57M	N/A	N/A	2,021	Earnings Report Analyst Forecast Short Interest Decrease
CALC CalciMedica	3.9214 of 5 stars	$0.72 -2.6%	$10.00 +1,285.0%	-72.3%	$11.41M	N/A	N/A	30	Earnings Report Analyst Forecast Short Interest Decrease Analyst Revision
KPRX Kiora Pharmaceuticals	3.0915 of 5 stars	$2.56 +0.8%	$10.00 +290.6%	+4.0%	$11.34M	$16.02M	N/A	10	Earnings Report Short Interest Decrease
PHXM PHAXIAM Therapeutics	N/A	$3.10 flat	N/A	N/A	$10.58M	N/A	N/A	49

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCNX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vaccinex (VCNX) Competitors

VCNX vs. INTS, CALC, KPRX, PHXM, and ADIL

How does Vaccinex compare to Intensity Therapeutics?

Summary

How does Vaccinex compare to CalciMedica?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Summary

How does Vaccinex compare to PHAXIAM Therapeutics?

Summary

How does Vaccinex compare to Adial Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vaccinex (VCNX) Competitors

VCNX vs. INTS, CALC, KPRX, PHXM, and ADIL

How does Vaccinex compare to Intensity Therapeutics?

Which has more risk and volatility, INTS or VCNX?

Does the media prefer INTS or VCNX?

Do institutionals and insiders have more ownership in INTS or VCNX?

Is INTS or VCNX more profitable?

Do analysts recommend INTS or VCNX?

Which has preferable valuation and earnings, INTS or VCNX?

Summary

How does Vaccinex compare to CalciMedica?

Which has more volatility & risk, CALC or VCNX?

Is CALC or VCNX more profitable?

Which has preferable earnings and valuation, CALC or VCNX?

Does the media refer more to CALC or VCNX?

Do institutionals & insiders believe in CALC or VCNX?

Do analysts rate CALC or VCNX?

Summary

How does Vaccinex compare to Kiora Pharmaceuticals?

Is KPRX or VCNX more profitable?

Do analysts recommend KPRX or VCNX?

Does the media refer more to KPRX or VCNX?

Which has preferable earnings & valuation, KPRX or VCNX?

Do institutionals and insiders believe in KPRX or VCNX?

Which has more volatility & risk, KPRX or VCNX?

Summary

How does Vaccinex compare to PHAXIAM Therapeutics?

Do institutionals and insiders have more ownership in VCNX or PHXM?

Does the media refer more to VCNX or PHXM?

Is VCNX or PHXM more profitable?

Which has preferable valuation & earnings, VCNX or PHXM?

Which has more risk and volatility, VCNX or PHXM?

Summary

How does Vaccinex compare to Adial Pharmaceuticals?

Which has more risk and volatility, ADIL or VCNX?

Which has higher earnings & valuation, ADIL or VCNX?

Does the media refer more to ADIL or VCNX?

Do institutionals & insiders believe in ADIL or VCNX?

Is ADIL or VCNX more profitable?

Do analysts rate ADIL or VCNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCNX vs. The Competition

Vaccinex Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools